Open Access
Vis Cancer Med
Volume 3, 2022
Article Number E1
Number of page(s) 3
Published online 26 April 2022
  1. Cabibbo G, Enea M, Attanasio M, et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010;51(4):1274–1283. [CrossRef] [PubMed] [Google Scholar]
  2. Khalaf N, Ying J, Mittal S, et al. Natural history of untreated hepatocellular carcinoma in a US Cohort and the role of cancer surveillance. Clinical Gastroenterology and Hepatology. 2017;15(2):273–281 e1. [CrossRef] [PubMed] [Google Scholar]
  3. Finn R, Qin S, Ikeda M, et al. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 2021;39(3_suppl):267. [CrossRef] [Google Scholar]
  4. Guarino M, Cucchetti A, Pontillo G, et al. Pattern of macrovascular invasion in hepatocellular carcinoma. European Journal of Clinical Investigation. 2021;51:e13542. [CrossRef] [PubMed] [Google Scholar]
  5. Chen ZH, Hong YF, Lin J, et al. Validation and ranking of seven staging systems of hepatocellular carcinoma. Oncology Letters. 2017;14(1):705–714. [CrossRef] [PubMed] [Google Scholar]
  6. Song P, Gao J, Inagaki Y, et al. Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china. Liver Cancer. 2013;2(1):31–39. [CrossRef] [PubMed] [Google Scholar]
  7. Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67(1):358–380. [CrossRef] [PubMed] [Google Scholar]
  8. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. Journal of hepatology. 2018;69(1):182–236. [CrossRef] [PubMed] [Google Scholar]
  9. Lyu N, Wang X, Li JB, et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1). Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2022;40(5):468–480. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.